Viewing Study NCT05503667

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 12:41 AM

Ignite Modification Date: 2025-12-25 @ 10:52 PM

Study NCT ID: NCT05503667

Status: RECRUITING

Last Update Posted: 2022-08-17

First Post: 2022-08-13

Is NOT Gene Therapy: False

Has Adverse Events: False

Brief Title: Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module